CJC-1295 / Ipamorelin Blend

CJC-1295/Ipamorelin Blend combines two complementary growth hormone-releasing peptides to create a synergistic formulation for advanced research applications. This combination pairs CJC-1295 (with DAC), a growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone-releasing peptide (GHRP).

**MECHANISM OF ACTION:** This blend leverages two distinct mechanisms of GH stimulation:

**CJC-1295 (GHRH Analog):** Binds to GHRH receptors on pituitary somatotrophs, stimulating growth hormone synthesis and release. The Drug Affinity Complex (DAC) modification extends plasma half-life through albumin binding, enabling sustained receptor activation.

**Ipamorelin (GHRP):** Acts through the ghrelin/GHS receptor pathway to potentiate GH release independent of GHRH signaling. This complementary mechanism amplifies the overall GH response.

**RESEARCH APPLICATIONS:** - Synergistic GH Release Studies - GHRH/GHRP Pathway Interaction Research - Pulsatile vs. Sustained GH Release Analysis - IGF-1 Axis Modulation - Extended Half-Life Peptide Research - Receptor Cross-Talk Investigations

**SYNERGY MECHANISM:** Published research suggests that combined GHRH analog and GHRP administration produces GH release greater than the sum of individual components. This synergistic effect is attributed to the distinct receptor pathways and complementary signaling cascades engaged by each peptide class.

**TECHNICAL SPECIFICATIONS:** - CJC-1295 MW: 3367.9 g/mol (with DAC modification) - Ipamorelin MW: 711.85 g/mol - Purity: >98% (HPLC) - Form: Lyophilized powder, pre-mixed ratio

**QUALITY ASSURANCE:** Each component verified for identity and purity. Full Certificate of Analysis provided.

FOR RESEARCH USE ONLY. Not for human consumption.